Insider Selling: Pharvaris (NASDAQ:PHVS) President Sells $610,200.00 in Stock

Pharvaris N.V. (NASDAQ:PHVS) President Peng Lu sold 15,000 shares of Pharvaris stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $40.68, for a total value of $610,200.00. Following the completion of the sale, the president directly owned 65,179 shares in the company, valued at $2,651,481.72. This represents a 18.71% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Peng Lu also recently made the following trade(s):

• On Thursday, June 18th, Peng Lu sold 300 shares of Pharvaris stock. The stock was sold at an average price of $34.00, for a total value of $10,200.00.

Pharvaris Trading Up 1.4%

Shares of PHVS stock opened at $38.02 on Friday. The stock has a 50 day simple moving average of $35.09 and a 200-day simple moving average of $31.38. The company has a market cap of $2.49 billion, a price-to-earnings ratio of -12.47 and a beta of -2.33. Pharvaris N.V. has a 12-month low of $20.65 and a 12-month high of $43.25.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). On average, equities analysts forecast that Pharvaris N.V. will post -3.12 earnings per share for the current fiscal year.

More Pharvaris News

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Pharvaris reported that once-daily extended-release deucrictibant reduced HAE attack rates by 83% versus placebo in the Phase 3 CHAPTER-3 trial. The result was statistically significant, with a p-value below 0.0001, and the study met its primary and secondary efficacy endpoints. The company plans to begin regulatory submissions in the first half of 2027. Pharvaris CHAPTER-3 topline data
• Positive Sentiment: The results strengthen Pharvaris’ potential to offer convenient oral treatments for both HAE prevention and acute attacks. Analysts believe the data could help the company gain market share in the HAE market. Pharvaris HAE market-share analysis
• Positive Sentiment: Analyst sentiment remains broadly favorable. Leerink Partners reiterated a Buy/Outperform view, while RBC Capital raised its price target to $62, Citizens JMP increased its target to $79, and HC Wainwright maintained a Buy rating with a $60 target. These revisions imply substantial upside from recent trading levels.
• Neutral Sentiment: Pharvaris is still a clinical-stage biotechnology company. Regulatory approval, launch execution, competition from established HAE therapies and continued cash requirements remain key risks. The company also recently reported a quarterly loss that was larger than analysts expected.
• Negative Sentiment: Director Robert Glassman sold 8,000 shares for approximately $300,400, reducing his direct holdings by 43.24%. President Peng Lu also sold 15,000 shares worth about $610,200, cutting his ownership by 18.71%. The insider selling may create a modest sentiment overhang, although it does not alter the favorable clinical results.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. venBio Partners LLC purchased a new stake in shares of Pharvaris in the 2nd quarter worth about $160,569,809. Deerfield Management Company L.P. lifted its holdings in shares of Pharvaris by 21.1% in the third quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock valued at $60,939,000 after purchasing an additional 425,000 shares in the last quarter. Wellington Management Group LLP grew its position in shares of Pharvaris by 12.9% in the second quarter. Wellington Management Group LLP now owns 2,392,934 shares of the company’s stock valued at $82,748,000 after purchasing an additional 274,034 shares during the last quarter. Commodore Capital LP grew its position in shares of Pharvaris by 1.6% in the first quarter. Commodore Capital LP now owns 1,918,970 shares of the company’s stock valued at $54,211,000 after purchasing an additional 29,525 shares during the last quarter. Finally, Paradigm Biocapital Advisors LP increased its stake in shares of Pharvaris by 72.7% during the 3rd quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company’s stock worth $45,796,000 after purchasing an additional 772,583 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on PHVS shares. HSBC upgraded shares of Pharvaris to an “overweight” rating in a research report on Thursday, August 13th. Leerink Partners raised their price objective on shares of Pharvaris from $50.00 to $65.00 and gave the company an “outperform” rating in a research note on Wednesday. UBS Group set a $79.00 price objective on shares of Pharvaris in a report on Wednesday. Guggenheim upped their target price on shares of Pharvaris from $40.00 to $44.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Wedbush increased their target price on shares of Pharvaris from $42.00 to $50.00 and gave the company an “outperform” rating in a report on Wednesday. Twelve investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $59.50.

About Pharvaris

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.